Skip to main content
SpringerLink
Log in

Mechanism Underlying the Strong Positive Inotropic Effects of LND-623: Specific Inhibition of Na, K-ATPase Isoforms and Exclusion of Cellular Sites of Contractile Control

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

LND-623 is a new aminosteroid analog of ouabain, with a greater separation between efficacy and toxicity than ouabain. To determine its mechanism of action, we studied its biochemical and physiological effects on human red blood cell sodium transports on different cellular structures regarded as sites of contractile control, and we compared its relative efficacy to ouabain in rat heart preparations and membrane-bound Na, K-ATPase isoenzymes. The response to ouabain was evaluated in Langendorff-perfused hearts and on purified membrane-bound Na, K-ATPase. LND-623 is 6.8-fold more efficient than ouabain in inhibiting the human Na+ pump (IC50= 0.098 ± 0.001 μM vs. 0.67 ± 0.02 μM); (P < 0.0001). LND-623 had no effect on the following cellular functions: Na-Ca exchange, Na-K cotransport, Ca-ATPase, slow calcium channels, adenylate cyclase system, phosphodiesterase, and calcium sensitivity of the contractile protein system. The dose–response curve for the positive inotropic and inhibitory effects on rat cardiac isoenzymes produced by LND-623 were clearly biphasic. The amplitude of the maximum inotropic effect, without any toxic effect, was up to three-fold higher with LND-623 than with the same maximum dose of ouabain used. The strong positive inotropic effect of LND-623 in rats could be related to a specific inhibition of the two rat cardiac isoforms of the Na, K-ATPase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Smith TW. Digoxin in heart failure. N Engl J Med 1993;329:51-53.

    Article  PubMed  Google Scholar 

  2. Gheorghiade M. Digoxin therapy in chronic heart failure. Cardiovasc Drugs Ther 1997;11:279-283.

    Article  PubMed  Google Scholar 

  3. Jarreau FX, Koening JJ, Fenard S. A new inotropic aminosteroid: LND623. Eur Heart J 1984;5:309-311.

    PubMed  Google Scholar 

  4. Adamantidis NM, Honoré ER, Dupuis BM. Electrical and mechanical effects of new aminosteroids on guinea pig isolated ventricular muscle. Br J Pharmacol 1988;95: 1063-1074.

    PubMed  Google Scholar 

  5. Maixent JM, Berrebi-Bertrand I, Lelièvre LG. Inhibition of cardiac Na, K-ATPase isozymes by LND-623. Biochem Pharmacol 1991;42:S223-S224.

    Article  PubMed  Google Scholar 

  6. Maixent J M, Berrebi-Bertrand I, Lelièvre L G, Fénard S. Efficacy and safety of the novel Na, K-ATPase inhibitor 20β R 14β-amino, 3β rhamnosyl, 5β pregnan, 20β-ol) in a model of heart failure. Arzn Forsch Drug Res 1992;42:1301-1305.

    Google Scholar 

  7. Schönfeld W, Weiland J, Repke KRH. Biochemical basis for the targeted synthesis of cardiac glycosides with selective action. In: Erdmann E, Greef, K, Skou JS, eds. Cardiac Glycosides (1785-1985). Darmstadt:, Steinkopff Verlag 1986:127-134.

    Google Scholar 

  8. Kawamoto RM, Pong SF, Simmons M, Chang YC, Maixent JM. Characterization of [3H] LND-796 binding to renal and neural and cardiac membrane fractions. Pharm Pharmacol Lett 1995;4:150-153.

    Google Scholar 

  9. Maixent JM, Gerbi A, Barbey O, Fénard S, Kawamoto RM, Baggioni A. Relation of plasma concentrations to positive inotropic effect of intravenous administration of cordil in dogs. Pharm Pharmacol Lett 1995;2:1-4.

    Google Scholar 

  10. Reiter M. Calcium mobilization and cardiac inotropic mechanisms. Pharmacol Rev 1988;40:189-217.

    PubMed  Google Scholar 

  11. Erdmann E, Philip G, Scholz H. Cardiac glycoside receptor Na,K-ATPase activity and force of contraction in rat heart. Biochem Pharmacol 1980;29:3219-3229.

    Article  PubMed  Google Scholar 

  12. Adams RJ, Schwartz A, Grupp G, et al. High affinity binding site and low-dose inotropic effect in rat myocardium. Nature 1982;296:167-169.

    PubMed  Google Scholar 

  13. Lelièvre LG, Maixent JM, Lorente P, Mouas C, Charlemagne D, Swynghedauw B. Prolonged responsiveness to ouabain in hypertrophied rat heart: Physiological and biochemical evidence. Am J Physiol 1986;250:H923-H931.

    PubMed  Google Scholar 

  14. Sweadner KJ. Isoenzymes of the Na,K-ATPase. Biochim Biophys Acta 1989;145:185-220.

    Google Scholar 

  15. Grupp I, Im WB, Lee CO, Lee SW. Relation of sodium pump inhibition to positive inotropy at low concentrations of ouabain in rat heart muscle. J Physiol 1985;360:149-160.

    PubMed  Google Scholar 

  16. Sweadner KJ. Multiple digitalis receptors, a molecular perspective. Trends Cardiovasc Med 1993;3:2-6.

    Article  Google Scholar 

  17. De Pover A, Grupp G, Schwartz A, Grupp IL. Coupling of contraction through effects on Na,K-ATPase: Changes in Na,K-ATPase isoforms in heart disease? Heart Failure 1990;1:201-258.

    Google Scholar 

  18. Maixent JM, Charlemagne D, De La Chapelle B, Lelièvre LG. Two Na,K-ATPase isoenzymes in canine cardiac myocytes: Molecular basis of inotropic and toxic effects of digitalis. J Biol Chem 1987;262:6842-6848.

    PubMed  Google Scholar 

  19. Mansier P, Lelièvre LG. Ca2+-free perfusion in rat heart reveals a Na, K-ATPase form highly sensitive to ouabain. Nature 1982;300:535-537.

    PubMed  Google Scholar 

  20. Janicot M, Desbuquois B. Fate of injected (125-I) cholera toxin taken up by rat liver in vivo: Generation of the active A1 peptide in the endosomal compartment. Eur J Biochem 1987;163:433-442.

    PubMed  Google Scholar 

  21. Garay RP, Diez J, Nazaret C, Dagher G, Abitbol JP. The interaction of canrenone with the Na,K-pump in human red blood cells. Naunyn Schiedebergs Arch Pharmacol 1985;329:311-319.

    Google Scholar 

  22. Chamberlain BK, Volpe P, Fleicher S. Inhibition of calcium induced calcium release from purified cardiac sarcoplasmic reticulum vesicles. J Biol Chem 1984;259:7540-7546.

    PubMed  Google Scholar 

  23. Solaro RJ, Ruegg JC. Stimulation of Ca2+ binding and ATPase activity of dog cardiac myofibrils by AR-L115BS, a novel cardiotonic agent. Circ Res 1982;51:290-294.

    PubMed  Google Scholar 

  24. Pitts BJR. Stoiechiometry of sodium/calcium exchange in cardiac sarcolemma vesicles. J Biol Chem 1979;254: 6232-6236.

    PubMed  Google Scholar 

  25. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 1974;58:541-546.

    PubMed  Google Scholar 

  26. Konas N, Lugnier C, Le Bec A, Serradeil-LeGal C, Barthelemy G, Stoclet JC. Differential sensitivity to cardiotonic drugs of cAMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. J Cardiovasc Pharmacol 1989;14:213-220.

    PubMed  Google Scholar 

  27. Khananshili D, Weil-Maslansky E. The cardiac Na/Ca exchanger: Relative rates of calcium and sodium movements and their modulation by protonation-deprotonation of the carrier. Biochemistry 1994;33:312-319.

    PubMed  Google Scholar 

  28. McGarry S, Williams AJ. Digoxin activates sarcoplasmic reticulum Ca2+-release channels: A possible role in cardiac inotropy. Br J Pharmacol 1993;108:1043-1050.

    PubMed  Google Scholar 

  29. Weingardt R, Marban E, Tsien RW. Is digitalis inotropy associated with enhanced slow inward calcium current? Nature 1978;273:389-391.

    PubMed  Google Scholar 

  30. Marban E, Tsien RW. Enhancement of calcium current during digitalis inotropy in mammalian heart: Positive feedback regulation by intracellular calcium? J Physiol 1982; 329:580-585.

    Google Scholar 

  31. Finkel MS, Romeo RC, Hartsell TL, Oddis CV. BAYK8644 is a negative inotropic in the presence of arachidonic acid but not eicopentaenoic acid. J Cardiovasc Pharmacol 1992; 20:563-571.

    PubMed  Google Scholar 

  32. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci USA 1992;89:1760-1764.

    PubMed  Google Scholar 

  33. Brown L. Positive inotropic and vasoconstrictor responses to 14 β-aminopregnane derivates in isolated tissues from guinea pig. Clin Exp Pharm Physiol 1990;17:589-594.

    Google Scholar 

  34. Shamraj OI, Grupp IL, Grupp G, et al. Characterization of Na/K-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts. Cardiovasc Res 1993;27:2229-2237.

    PubMed  Google Scholar 

  35. Zahler R, Gimore-Hebert M, Baldwin JC, Franco K, Benz EJ, Jr. Expression of isoforms of the Na,K-ATPase in human heart. Biochim Biophys Acta 1993:1149:189-194.

    PubMed  Google Scholar 

  36. Barbey O, Gerbi A, Robert K, Mayol V, Pierre S, Paganelli, Maixent JM. Immunological identification of Na,K-ATPase alpha subunit isoforms in nonfailing and failing myocardium. Ann NY Acad Sci 1997;834:658-660.

    PubMed  Google Scholar 

  37. Askew GR, Lingrel JB, Grupp IL, Grupp G. Direct correlation of Na,K-ATPase-isoform abundance and myocardial contractility in mouse heart. In: E. Bamberg, W Schoner, eds. The Sodium Pump: Structure, Mechanism, Hormonal Control and its Role in Disease. Darmstadt: Steinkopff; New York: Springer, 1994:718-721.

    Google Scholar 

  38. Maixent JM, Gerbi A, Berrebi-Bertrand I, Correa P, Genain G, Baggioni A. Cordil reversibly inhibits the Na, K-ATPase from outside of the cell membrane. Role of K-dependent dephosphorylation. J Recept Res 1993;13:1083-1092.

    PubMed  Google Scholar 

  39. Maixent JM, Fénard S, Kawamoto RM. Tissue localization of active Na,K-ATPase isoenzymes by determination of their profile of inhibition with ouabain, digoxin, digitoxigenin and LND 796, a new aminosteroid cardiotonic. J Recept Res 1991;11:687-698.

    PubMed  Google Scholar 

  40. Scholtysik K, Salzmann R, Berthold R, Herzig JN, Quast U, Markstein R. DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties. Naunyn Schiedebergs Arch Pharmacol 1988;329:316-325.

    Google Scholar 

  41. Malloy KJ, David BC, Dhillon DS. LND-796, a potent cardiotonic drug with improved safety vs. digoxin(abstr). Circulation 1989;80:S129.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Recherche Cardiologique, Faculté de Médecine, Université de la Méditerranée, Marseille, France

    Jean-Michel Maixent & Isabelle Berrebi-Bertrand

  2. Laboratoire de Pharmacologie des Transports Ioniques Membranaires, Hall des Biotechnologies, Université Paris VII, Paris, France

    Lionel Lelièvre

Authors
  1. Jean-Michel Maixent
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lionel Lelièvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabelle Berrebi-Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maixent, JM., Lelièvre, L. & Berrebi-Bertrand, I. Mechanism Underlying the Strong Positive Inotropic Effects of LND-623: Specific Inhibition of Na, K-ATPase Isoforms and Exclusion of Cellular Sites of Contractile Control. Cardiovasc Drugs Ther 12, 585–594 (1998). https://doi.org/10.1023/A:1007747623749

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007747623749

Search

Navigation